drugset / Trial / NCT06468202
Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL
Phase 4
Recruiting
10742 enrolled
Ohio State University
Northwestern University · collabPatient-Centered Outcomes Research Institute · collabPreeclampsia Foundation · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The overall goal of this large, pragmatic, comparative effectiveness trial is to test the hypothesis that among at-risk individuals, 162 mg/day aspirin is superior to 81 mg/day in preventing Hypertensive disorders of pregnancy (HDP), and that there are multiple factors associated with adherence with aspirin therapy that will be important to identify to enable optimal implementation of study findings and population-level benefits.
Timeline
- Start
- 2024-10-18
- Primary completion
- 2029-01-01
- Completion
- 2030-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | 81 mg | — |
| Subject | Aspirin | Small molecule | 162 mg | — |